S&P Futures
5,893.25 -3.00 (-0.05%) Dow Futures
43,153.00 -24.00 (-0.06%) Nasdaq Futures
20,504.00 -15.50 (-0.08%) Russell 2000 Futures
2,252.40 -3.10 (-0.14%) Crude Oil
70.54 -0.02 (-0.03%) Gold
2,738.50 -0.40 (-0.01%)
Estrella Immunopharma, Inc. (ESLAW)
| Previous Close | 0.0990 |
| Open | 0.0990 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.1225 - 0.1225 |
| 52 Week Range | 0.1225 - 0.1225 |
| Volume | |
| Avg. Volume | N/A |
| Market Cap | N/A |
| Beta (5Y Monthly) | -0.09 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireEstrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells
EMERYVILLE, Calif., September 27, 2024--Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient enrolled in its STARLIGHT-1 Phase I/II clinical trial has achieved a complete response (CR) one month after receiving an infusion of EB103 CD19- Redirected ARTEMIS® T Cells.
Business WireEstrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member
EMERYVILLE, Calif., August 14, 2024--Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) ("Estrella", "Estrella Immunopharma", or the "Company"), a clinical stage biopharmaceutical company focused on developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancers and autoimmune diseases, today announced the appointment of Hong Zhang as Chairperson and a member of its Board of Directors. This appointment comes shortly after the Company dosed the first patient in its Phase I/II clinical
